Dr. James F. Dillman III is currently the Director of Research at the United States Army Medical Research Institute of Chemical Defense. He serves as the Senior Civilian Scientist and oversees a program focused on the research and development of medical countermeasures against chemical and biochemical threats to protect Warfighters as well as Civilians. He serves as the Command advisor for scientific and research matters related to medical chemical defense.
He served previously as the Chief of the Science Program Analysis and Integration Office and was a Principal Investigator in the Cell and Molecular Biology Branch at the United States Army Medical Research Institute of Chemical Defense. As a Principal Investigator, Dr. Dillman oversaw a research group focused on the development of medical countermeasures to chemical warfare agents. His research group utilized transcriptomics, proteomics and molecular approaches to define the molecular and cellular consequences of chemical warfare agent exposure with the goal of identifying therapeutic targets for development of toxicant medical countermeasures.
Dr. Dillman received a B.S. with honors in biology from Lebanon Valley College of Pennsylvania, and his Ph.D. from the Department of Cell Biology at the University of Virginia. He was awarded post‐doctoral fellowships from the National Stroke Association and the National Institutes of Health during his time as a research fellow in the Departments of Neurology and Neuroscience at the Johns Hopkins University School of Medicine. He joined the United States Army Medical Research Institute of Chemical Defense as a National Research Council Research Associate and subsequently came on staff as a principal investigator in the Applied Pharmacology Branch at the United States Army Medical Research Institute of Chemical Defense.
